Last reviewed · How we verify
Tylenol #3 Oral Tablet
At a glance
| Generic name | Tylenol #3 Oral Tablet |
|---|---|
| Also known as | codeine-acetaminophen, Atasol |
| Sponsor | Minerva A Romero Arenas |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis (NA)
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (PHASE3)
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- Musculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries (PHASE4)
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (PHASE2)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- Multimodal Analgesia Strategies After Major Shoulder Ambulatory Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tylenol #3 Oral Tablet CI brief — competitive landscape report
- Tylenol #3 Oral Tablet updates RSS · CI watch RSS
- Minerva A Romero Arenas portfolio CI